Colorectal cancer screening

Journal of Internal Medicine

Volumn 270, Issue 2, 2011, Pages 87-98

  Bretthauer, M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colorectal cancer; Endoscopy; Large bowel; Prevention; Screening

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLON HEMORRHAGE; COLON PERFORATION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DENMARK; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FINLAND; HEALTH CARE COST; HUMAN; ICELAND; META ANALYSIS (TOPIC); NORWAY; OCCULT BLOOD TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SWEDEN; TREND STUDY;

COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; MASS SCREENING; OCCULT BLOOD; SIGMOIDOSCOPY;

EID: 79960262064     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02399.x     Document Type: Review

References (49)

1. Globocan 2002 database. (accessed 22.02.10).
2. Engholm G, Ferlay F, Christensen N et al. NORDCAN: cancer incidence, mortality, prevalence and prediction in the Nordic Countries, Version 3.5. Association of the Nordic Cancer Registries. 2009 Danish Cancer Society.
3. Ries L, Melbert D, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute, 2007.
4. Lindgren G, Liljegren A, Jaramillo E et al. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut 2002; 50: 228-34.
5. Burt RW, Bishop DT, Lynch HT et al. Risk and surveillance of individuals with heritable factors of colorectal cancer. WHO Bulletin OMS 1990; 88: 655-65.
6. Rex D, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol 2000; 95: 868-77.
7. Wilson JMG, Jungner YG. Principles and Practice of Mass Screening for Disease. Geneva: WHO, 1968.
8. Kalager M, Zelen M, Langmark F et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203-10.
9. rsa Lv, Anttila A, Ronco G et al. Cancer screening in the European Union. Report on the implementation of the council recommendation on cancer screening - First Report. European Commission, Luxembourg 2008.
10. Hewitson P, Glasziou P, Watson E et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-9.
11. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
12. Malila N, Oivanen T, Malminiemi O, Hakama M. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 2008; 337: a2261.
13. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Practice Res Clin Gastroenterol 2010; 24: 479-92.
14. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
15. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-9.
16. Lansdorp-Vogelaar I, van Ballegoijen M, Zauber AG et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101: 1412-22.
17. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
18. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13years and seven biennial screening rounds. Gut 2002; 50: 29-32.
19. Kronborg O, Jorgensen OD, Fenger C et al. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004; 39: 846-51.
20. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71.
21. Mandel JS, Church TR, Ederer F et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-7.
22. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
23. Robinson MH, Hardcastle JD, Moss SM et al. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999; 45: 588-92.
24. Lindholm E, Brevinge H, Haglin E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95: 1029-36.
25. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 30: 343.
26. Zheng S, Chen K, Liu X et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum 2003; 46: 51-8.
27. Hanley JA. Analysis of mortality data from cancer screening studies. Looking in the right window. Epidemiology 2005; 16: 786-90.
28. Levin B, Liebrman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on colorectal cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.
29. Levin TR, Farraye FA, Schoen RE et al. Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut 2005; 54: 807-13.
30. Imperiale TF, Wagner DR, Lin CY et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-74.
31. Atkin W, Rogers P, Cardwell C et al. Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. Gastroenterology 2004; 126: 1247-56.
32. Bretthauer M, Skovlund E, Grotmol T et al. Inter-endoscopist variation in polyp and neoplasia pick-up rates in flexible sigmoidoscopy for colorectal cancer screening. Scand J Gastroenterol 2003; 38: 635-42.
33. Fracchia M, Senore C, Armaroli P et al. Assessment of the multiple components of the variability in the adenoma detection rate in sigmoidoscopy screening, and lessons for training. Endoscopy 2010; 42: 448-55.
34. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999; 34: 414-20.
35. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
36. Hoff G, Grotmol T, Skovlund E, Bretthauer M, for the Norwegian Colorectal Cancer Prevention Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised trial. BMJ 2009; 338: B1846.
37. Cuzick J, Cafferty FH, Edwards R, Møller H, Duffy SW. Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial. J Med Screen 2007; 14: 178-85.
38. Bretthauer M. Which tool is best for colorectal cancer screening? Flexible sigmoidoscopy shows promise, but randomised data are needed BMJ 2010; 340: c2831.
39. Weissfeld JL, Schoen RE, Pinsky PF et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005; 97: 989-97.
40. Segnan N, Senore C, Andreoni B et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE. J Natl Cancer Inst 2002; 94: 1763-72.
41. Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-8.
42. Hoff G, Dominitz JA. Contrasting US and European approaches to colorectal cancer screening: which is best? Gut 2010; 59: 407-14.
43. Ransohoff DF. Have we oversold colonoscopy? Gastroenterology 2005; 129: 1815.
44. Colorectal cancer screening in average-risk population: immunochemical 11 fecal occult blood testing versus colonoscopy. ClinicalTrials.gov.
45. Northern-European Initiative on Colorectal Cancer (NordICC). ClinicalTrials.10 gov.
46. Fretheim A, Bretthauer M. Results from clinical effectiveness evaluations of screening for colorectal cancer. The Norwegian Knowledge Centre for the Health Services on behalf of The Norwegian Council for Quality Improvement and Priority Setting in Health Care, Oslo 2010.
47. The Lancet. The trouble with screening. Lancet 2009; 373: 1223.
48. Allison J. Colorectal cancer screening guidelines: the importance of evidence and transparency. Gastroenterology 2010; 138: 1648-52.
49. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol 2010; 24: 417-25.